Research Article
Isolated IgA Anti-β2 Glycoprotein I Antibodies in Patients with Clinical Criteria for Antiphospholipid Syndrome
Table 3
Positive aPL antibodies in C-APS patients versus controls.
| | Controls () | APS () | OR | |
| aB2GPI IgG | 2 (0.6%) | 14 (8.9%) | 14.9 | <0.0001 | aB2GPI IgM | 3 (0.9%) | 8 (5.1%) | 5.4 | 0.0146 | aB2GPI IgA | 5 (1.6%) | 45 (28.8%) | 24.4 | <0.0001 | aCL IgG | 3 (0.9%) | 17 (10.8%) | 12.3 | <0.0001 | aCL IgM | 2 (0.6%) | 8 (5.1%) | 8.2 | 0.0053 | aCL IgA | 3 (0.9%) | 8 (5.1%) | 5.5 | 0.0148 | aB2GP1 IgA (isolated) | 5 (1.6%) | 35 (22.4%) | 17.4 | <0.0001 | aCL or aB2GPI (IgG or IgM) | 6 (2.0%) | 22 (14.1%) | 8.2 | <0.0001 | aCL or aB2GPI any isotype | 13 (4.2%) | 61 (39.1%) | 14.5 | <0.0001 |
|
|